BioXcel cuts CEO/CFO/CSO 2025 cash comp, grants stock options at $0.4713

BioXcel Therapeutics, Inc.

CEO Vimal Mehta's 2025 cash compensation reduced to $706,558; granted options for 660,000 shares at $0.4713.
CFO Richard Steinhart's cash comp reduced to $289,800; granted options for 270,000 shares.
CSO Frank Yocca's cash comp reduced to $290,500; granted options for 270,000 shares.
Options vest in 12 equal monthly installments; full acceleration on termination without cause or change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.